SK Plasma Signs MOU for Blood Product Investment with Indonesian Sovereign Wealth Fund

Full-Scale Investment Talks Begin with Danantara Indonesia, Launched This Year
Securing Essential Medicine Production Facilities Expected to Reduce Import Dependence and Boost Self-Sufficiency

SK Plasma is receiving continued interest from local sovereign wealth funds for its blood product manufacturing facility currently under construction in Indonesia.

Noh Hyunho, Head of SK Plasma Core Corporation (right), and Pandu Jahirir Danantara, Chief Investment Officer, are posing for a commemorative photo after signing the MOU for investment in blood product manufacturing infrastructure held locally in Indonesia. SK Plasma

On November 10, SK Plasma announced that it had signed a Memorandum of Understanding (MOU) with Danantara Indonesia, an Indonesian sovereign wealth fund, for investment in blood product manufacturing infrastructure. This marks the second case of collaboration following SK Plasma's investment agreement with the Indonesia Investment Authority (INA) last year, the first such agreement by a Korean company.

Under the MOU, the two companies will begin full-scale discussions regarding the direction and procedures for SK Plasma Core's investment in Indonesia. SK Plasma Core is a joint venture established to build blood product manufacturing facilities in Indonesia, with SK Plasma as the largest shareholder and INA as the second-largest shareholder.

Danantara was launched earlier this year as Indonesia's second sovereign wealth fund, following INA. Danantara has identified healthcare as one of its eight core sectors, alongside minerals and renewable energy, and has announced plans to invest in plasma and healthcare-related infrastructure.

Danantara stated that the MOU was signed to reduce Indonesia's reliance on imports of plasma-derived medicines and to secure self-sufficiency in essential pharmaceuticals. Starting with investment in the blood product business, Danantara plans to expand cooperation to strengthen Indonesia's essential medical infrastructure.

Pandu Zahri Danantara, Chief Investment Officer of Danantara, said, "Reducing dependence on imports for essential medical services and establishing a stable national healthcare system is one of our key investment strategies. This MOU marks an important milestone in building world-class healthcare infrastructure at the national level through investment based on SK Plasma's technological expertise."

SK Plasma plans to successfully complete the Indonesian blood product project through close collaboration with existing shareholders, including INA, as well as sovereign wealth funds such as Danantara.

Kim Seungjoo, CEO of SK Plasma, stated, "The Karawang production facility being built by SK Plasma Core is more than just a pharmaceutical plant; it is a national project directly linked to the health of the Indonesian people and the sovereignty of essential medicines. Through close cooperation with major Indonesian government agencies, including sovereign wealth funds, we will ensure the seamless construction of a production facility capable of stably supplying high-quality blood products."

Meanwhile, SK Plasma has secured the blood product business license from the Indonesian Ministry of Health and established the joint venture SK Plasma Core to build the blood product plant. The new facility, scheduled to begin operations in the fourth quarter of 2026, will be located within the Karawang Industrial Complex, occupying a site of approximately 49,000 square meters, and will fractionate 600,000 liters of plasma annually to produce blood products such as albumin and immunoglobulin.

This content was produced with the assistance of AI translation services.